Introduction {#S1}
============

In economically developed regions of the world, 8 to 10% of the annual new cancer diagnoses account for hematological malignancies (HM) and one-third of the HM patients are expected to die of their disease ([@B19]; [@B28]; [@B7]; [@B54])^[1](#footnote1){ref-type="fn"}^. Lymphoid neoplasm represents about three-quarters of all HM, and within this group, mature B-cell malignancies dominate (source^[2](#footnote2){ref-type="fn"}^) ([@B74]).

Since 2001, the World Health Organization (WHO) has provided and updated consensus classification of HM based on cell lineage, genetic abnormalities, and clinical features, which defines over 60 disease subtypes in the latest 2016 edition ([@B3]). Diagnosis of HM is increasingly complex and relies on new sophisticated laboratory technologies that are not available worldwide. Therefore, disparities between geographical areas in terms of HM incidence and survival can result from: diversity among HM that complexifies standardized categorizations; heterogeneity of reporting systems, registries, and methodologies of reports; geographic and ethnic differences in endogenous and exogenous conditions at higher risk of HM occurrence, including genetic, toxic, and viral factors; variations in access to drugs and their metabolism ([@B65]; [@B19]; [@B28]; [@B49]; [@B45]).

Besides the underlying patient's conditions, the type and stage of the hematologic disease, acute intercurrent events such as infections can significantly modulate the prognosis. In a 14-year prospective longitudinal surveillance study conducted at a regional cancer center in United Kingdom, patients with HM had a 3-fold higher incidence of blood stream infections (BSIs) than patients with other cancers ([@B71]). Infection-related mortality in HM patients can be high due to weak immune systems and the accumulation of various factors such as neutropenia, excessive or repeated chemotherapy, long hospital stays, and hospital-acquired infections.

Since the spread of Gram-negative (GN) bacteria producing the extended spectrum ß-lactamase (ESBL) enzymes, which, in addition to penicillins, confer resistance to cephalosporins and monobactam ([@B81]), carbapenems have been used as last-line antibiotics to treat infection caused by this type of bacteria ([@B47]). Unfortunately, shortly after the use of carbapenems, fermenters (Enterobacteriaceae), and non-fermenters (*Pseudomonas aeruginosa* and *Acinetobacter baumannii*), GN-bacteria rapidly developed resistance to this antibiotic family and spread throughout the world ([@B8]). Several carbapenem resistance mechanisms have been developed by GN-bacteria, including the production of carbapenemase enzymes, which is nowadays identified worldwide ([@B57]).

Regarding the major concern raised by the global expansion of carbapenem resistance associated with significant global mortality ([@B11]; [@B29]), we focused on morbidity and mortality related to carbapenem resistance in adult patients with HM. We reviewed series and case reports of carbapenem-resistant (CR) GN-bacteria in this targeted population to describe the epidemiologic and clinical factors associated with the occurrence of CR infections. We collected data on antimicrobial susceptibility and the provided antibiotic treatments. We aimed at identifying key points that could help assess the risk of CR infection in HM patients and improve their survival.

Methods {#S2}
=======

In this review, we reviewed series and selected case reports that reported colonization or infection of HM patients with CR bacteria. The electronic literature search was conducted in two electronic databases, Pubmed and Google Scholar. Papers published from January 2010 to January 2019 and written in English were included. A panel of keywords was used to target articles that address the topic of our review, including "bacteria," "Gram negative," "Enterobacteriaceae," "*Klebsiella pneumoniae*," "*Escherichia coli*," "*Acinetobacter baumannii*," "*Pseudomonas aeruginosa*," "carbapenem resistance," "carbapenemase," "KPC," "NDM," "OXA," "hematological malignancy," "leukemia," "colonization," "infection," "blood stream infection," "bacteremia," "neutropenia," and "chemotherapy." Only papers reporting cases of colonization or infection with CR bacteria in adult HM patients were selected. The following data were extracted from each study: study type, region, published year, study period, number of patients included, age, HM-type, CR-bacterial genera or species, sample, CR mechanism, antibiotic susceptibility profile of CR bacteria, comorbidity, significative risk factors associated with occurrence of CR bacteria, mortality associated with CR bacteria, significative risk factors of mortality associated with CR bacteria, and provided antibiotic treatments. A targeted search was performed to find the recommendations from medical societies for the management of neutropenic febrile patients and to document the use of new antibiotics to treat CR bacteria, selecting only the most recent references.

Results and Discussion {#S3}
======================

Based on our inclusion criteria, a total of 31 publications treating cases of colonization or infection by CR bacteria in adult HM patients were selected to conduct our review. Eighteen series (two prospective monocentric, three prospective multicentric, nine retrospective monocentric, and four retrospective multicentric) and 13 case reports published between 2012 and 2018 treated the topic that were conducted in 16 different countries, including: Australia (1/16), Brazil (1/16), China (6/16), Egypt (1/16), Germany (1/16), Greece (1/16), India (1/16), Israel (1/16), Italy (8/16), Japan (1/16), Poland (1/16), Spain (1/16), Sweden (1/16), Turkey (1/16), United Kingdom (1/16), and United States (3/16) ([Figure 1](#F1){ref-type="fig"}; [Tables 1](#T1){ref-type="table"}−[4](#T4){ref-type="table"}). Depending on HM patient's recruitment criteria used by the studies, 23/31 included cases of infections with CR bacteria, 2/31 included cases of colonization with CR bacteria, and 6/31 included both ([Tables 1](#T1){ref-type="table"}−4). Only 12 out of the 31 articles reported the CR mechanism ([Figure 1](#F1){ref-type="fig"}; [Tables 1](#T1){ref-type="table"}−[4](#T4){ref-type="table"}). The production of carbapenemase enzymes was the only mechanism described with the predominance of KPC (*K. pneumoniae* carbapenemase) enzyme (8/12) followed by NDM \[New Delhi metallo-ß-lactamases (MBL)\] (2/12), VIM (Verona integron-encoded MBL) (1/12), and IMI (imipenem resistant variant 1) (1/12) enzymes ([Figure 1](#F1){ref-type="fig"}; [Tables 1](#T1){ref-type="table"}−4). Thirteen publications reported some significative risk factors associated with occurrence of CR bacteria in HM patients ([Table 1](#T1){ref-type="table"}). The mortality rate associated with CR bacteria was indicated in 14 publications where 10 of them described also significative risk factors of mortality associated with CR bacteria ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Data on therapeutic management of CR bacteria in adult HM patients (neutropenic or not) were provided in only eight publications ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

![Worldwide distribution of carbapenemase enzymes depending on their regional endemicity or significant outbreak situation and geolocation of studies reporting the occurrence of CR bacteria isolated in HM patients. AA, aplastic anemia; AL, acute leukemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, Chronic myeloid leukemia; HL, Hodgkin's lymphoma; HM, hematologic malignancy; MDS, myelodysplatic syndrome; MM, myelome multiple; NHL, Non-Hodgkin's lymphoma.](fmicb-11-01422-g001){#F1}

###### 

Characteristics of the studies reporting factors associated with CR bacteria in HM patients.

                        **Study**                                        **Period**           **Place**                 **Type**                                                                                                         **Recruitment**                                                                        **Global effective**                                                                     **CR Effective**                                                                                                                 **Hematologic malignancies**                                             **Associated conditions**                                                                                                            **Significant risk factors for CR**
  --------------------- ------------------------------------------------ -------------------- ------------------------- ---------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------
  **Asia**              ([@B42]) ***Mjhid***                             10/2013--01/2016     New Delhi, India          prospective monocentric                                                                                          consecutive newly diagnosed with HM hospitalized patients (no previous chemotherapy)   225                                                                                      94/225 patients with CR-bacteria colonization (48/94 at admission) and 17/94 with CR-BSI                                         19 ALL, 37 AML, 22 lymphoma, and others                                  NA                                                                                                                                   AML, duration of hospitalization for CR-colonization, all CR-BSI occurred in CR-carriers
                        ([@B89]) ***Eur J Clin Microbiol Infect Dis***   01/2014--06/2015     Jiangsu Province, China   retrospective multicentric (18 tertiary hospitals)                                                               *A. baumannii* bacteremia in HM patients                                               3158 patients, 2133 GN isolates, 1358 BSI, 40 *A. baumannii-*BSI                         13/40 *A. baumannii-*BSI                                                                                                         25 AL, 6 NHL, 4 MM, 2 AA, 2 MDS, 1 CLL                                   27/40 neutropenic, 16/40 central venous catheter                                                                                     longer hospital stays, previous use of carbapenem, at least three types of antimicrobial therapy received before bacteremia
  **Middle east**       ([@B1]) ***J Antimicrob Chemother***             2008--2014           Haifa, Israel             retrospective monocentric                                                                                        GN BSI in HM patients                                                                  330 patients; 423 GN BSI                                                                 91/330 patients; 103/423 BSI                                                                                                     264/423 AL and MDS, 159/423 others (CL or lymphoma or MM)                364/423 nosocomial BSI, 388/423 central venous catheter, 53/103 carbapenem treatment 30 days before CR BSI                           known CR carriage, salvage chemotherapy, urinary catheters, nasogastric tube, longer admission period, lower albumin level, hypotension
                        ([@B44]) ***Infect Dis***                        01/2005--12/2009     Ankara, Turkey            retrospective monocentric                                                                                        BSI in HM patients                                                                     2098 HM patients, 281 with BSI representing 536 BSI episodes                             11,5% of GN isolates                                                                                                             66 AML, 47 ALL, 6 MDS, 69 NHL, 37 MM, 14 HL, 13 CL, 7 AA, others         3703 neutropenic episodes                                                                                                            NA
  **Northern europe**   ([@B6]) ***PlosOne***                            2007--2015           Frankfurt, Germany        retrospective monocentric                                                                                        AML patients undergoing intensive induction chemotherapy                               220 AML patients, 90/220 colonized at admission                                          12/90 patients colonized with CR-bacteria                                                                                        AML                                                                      100% induction chemotherapy (cytarabine, daunorubicin) and levofloxacin 500 mg daily as prophylaxis                                  NA
                        (Schlenz et al., 2013) ***JAC***                 1997--2010           Norwich, United Kingdom   prospective monocentric                                                                                          BSI in HM and solid cancer patients                                                    HM patients: 473 BSI and 488 isolates; solid cancer patients: 441 BSI and 461 isolates   2, 5% among GN BSI in HM patients and less than 1% in solid cancer patients                                                      NA                                                                       NA                                                                                                                                   NA
  **Southern europe**   ([@B79]) ***CMI***                               2009--2012           Rome, Italy               prospective multicentric (9 hematology wards at tertiary care centers or at university hospitals)                consecutive HM patients bacterial BSI                                                  575 healthcare and community-acquired BSI; 668 bacterial isolates; 344 GN                67 isolates                                                                                                                      NA                                                                       529/575 neutropenic (92%)                                                                                                            NA
                        (Pagano et al., 2014) ***Emerg Infect Dis***     01, 2009--12, 2012   Rome, Italy               retrospective monocentric                                                                                        HM patients admitted to hospital with KPC-Kp BSI                                       147 GN BSI                                                                               26/147 GN BSI representing 26/38 *Kp*-BSI                                                                                        14 AML, 4 NHL, 3 ALL, 2 HL, 1 AA, 1 MDS, 1 myelo-proliferative disease   13/26 initial or consolidation chemotherapy, 19/26 neutropenic                                                                       NA
                        ([@B35]) ***Bone Marrow Transplantation***       01, 2010--07, 2013   Italy                     retrospective multicentric (52 transplant centers)                                                               HM patients undergoing HSCT                                                            6058 auto-HSCT and 4389 allo-HSCT patients                                               CR-*Kp* colonization in 31 auto-HSCT and 51 allo-HSCT patients. CR-*Kp* infection in 25 auto-HSCT and in 87 allo-HSCT patients   40 AML, 18 ALL, 26 lymphoma, 8 MM, 20 others                             84 neutropenia, 27 GVHD, CR-*Kp* previous colonization in 8 auto-HCST patients with CR-*Kp* infection and in 20 allo-HSCT patients   
                        ([@B80]) ***AJH***                               01, 2010--06, 2014   Italy                     prospective multicentric cohort study (13 hematological wardsof tertiary care centers or university hospitals)   hospitalized HM patients with *Kp* BSI                                                 278 Kp-BSI                                                                               161/278                                                                                                                          119 AML, 1 CML, 12 ALL, 1 CLL, 18 NHL, 3 MM, 2 MDS                       129/161 chemotherapy, 71/161 corticosteroids                                                                                         peripherally inserted central catheters (PICCs), AML, previous CR-*Kp* rectal swabs, antibiotic prophylaxis with fluoroquinolones
                        ([@B55]) ***BMC ID***                            02, 2012--05, 2013   Rome, Italy               retrospective monocentric                                                                                        CR-*Kp* BSI in hospitalized HM patients                                                NA                                                                                       22 patients with CR-*Kp* colonization and 14 with CR-*Kp* BSI                                                                    16 AL (12 AML) and others                                                5/22 recent carbapenem, 10/22 neutropenia, 20/22 chemotherapy                                                                        AML independent risk factor for bacteremia onset in carriers
                        ([@B16]) ***Annals of Hematology***              03, 2015--08, 2015   Italy                     prospective multicentric (18 hematological institutions)                                                         consecutive HM patients admitted to hematological wards                                144 patients with MDR-bacteria rectal carriage incidence 6,5%                            85/144 patients with CR-colonization, 12/85 with CR BSI                                                                          29/85 AML; 8/85 ALL; 32/85 lymphoma; 8/85 MM                             12/85 salvage chemotherapy                                                                                                           for CR-BSI: urinary catheters, relapsed/refractory HM
  **United States**     ([@B68]) ***Leukemia and Lymphoma***             07, 2007--12, 2010   New York, United States   retrospective monocentric                                                                                        CR-BSI in HM patients                                                                  NA                                                                                       18 patients                                                                                                                      8 AL, 4 lymphoma or MM                                                   13/18 neutropenia, 13/18 chemotherapy 16/18 prior systemic antibacterial therapy, 6/18 HSCT, 16/18 prior hospitalization             NA

AA, aplastic anemia; AL, acute leukemia; ALL, acute lymphoid leukemia; allo-, allogenic; AML, acute myeloid leukemia; auto-, autologous; BSI, blood steam infection; CL, chronic lymphoma, CLL, chronic lymphocytic leukemia; CML, Chronic myeloid leukemia; CR, carbapenem-resistant; GN, Gram-negative;, GVHD, graft vs. host disease; HL, Hodgkin' s lymphoma; HM, hematologic malignancy; HSCT, hematologic stem cell transplantation; Kp, Klebsiella pneumoniae; MDR, multidrug resistant; MDS, myelodysplatic syndrome; MM, myelome multiple; NHL, Non-Hodgkin's lymphoma.

###### 

Characteristics of the studies reporting therapeutic management and mortality associated with CR bacteria in HM patients.

                        **Study**                                           **Period**           **Place**                 **Age (year)**                                          **CR Species**                                                                                                    **CR-Susceptibility (S) or resistance (R)**                                                                                      **Therapeutic regimens**                                                                                                                                                                                 **Mortality**                                                              **CR-related mortality**                                                                                                                    **Mortality risk Factors**
  --------------------- --------------------------------------------------- -------------------- ------------------------- ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  **Asia**              ([@B42]) ***Mjhid***                                10, 2013--01, 2016   New Delhi, India          46 and 49 \[2--75\] (medians \[range\])                 *Kp* \> *E. coli* colonization (mainly hospital acquisition), 12/17 BSI with *Kp* and 5/17 with *E. coli*         100% colistin S; 7/12 (58%) *Kp* and 4/5 (80%) *E coli* tigecycline S; 1/12 (8%) *Kp* and 1/5 (20%) *E. coli* aminoglycoside S   NA                                                                                                                                                                                                       9,5% global infection related mortality over 26 months                     17/17 (100%) deaths in CR-BSI                                                                                                               AL, nosocomial acquisition
                        ([@B89]) ***Eur J Clin Microbiol Infect Dis***      01, 2014--06, 2015   Jiangsu Province, China   55% \<60                                                *A. baumannii*                                                                                                    100% colistin S, 91% tigecycline S and 76% amikacin S                                                                            Effective treatment in 20/40 (50%) *A. baumannii* BSI                                                                                                                                                    32,5% at 30 days                                                           8/13 (62%)                                                                                                                                  APACHE score, CR: independent risk factors for 30-day mortality in *A. baumannii* BSI
  **Middle east**       ([@B1]) ***J Antimicrob Chemother***                2008--2014           Haifa, Israel             50 ± 15 (mean ± SD)                                     45% *Kp*, 25% *polymicrobial*, 15% *P. aeruginosa*, 13% *E. coli*, 13% S. *maltophila*, 9% *Acinetobacter* spp.   NA                                                                                                                               35/103 (34%) appropriate empirical antibiotic treatment, 58/103 (56%) colistin                                                                                                                           95/423 BSI (22%) at 14 days; 187/330 patients (57%) at 1 year              47/103 BSI (45,6%) at 14 days; 68/91 patients (74%) at 1 year                                                                               NA
  **Europe**            ([@B6]) ***PlosOne***                               2007--2015           Frankfurt Germany         60,5 \[18--85\] (median, \[range\])                     Enterobacteriaceae                                                                                                NA                                                                                                                               NA                                                                                                                                                                                                       8% at 2 months, 25% at 1 year and 41.5% at 2 years in colonized patients   33% at 2 months, 67% at 1 year and 75% at 2 years in CR-colonized patients                                                                  significantly reduced 60- and 90-day, as well as 1-and 2-year survival rates in CR-colonized patients (vs. non-colonized)
  **Southern europe**   ([@B79]) ***CMI***                                  2009--2012           Rome, Italy               52 ± 14 (mean, SD)                                      *15 Kp, 47 Pseudomonas* spp. *3 E. coli, 2 E. cloacae*                                                            2/110 (2%) BGN tested colistin R (*Pseudomonas putida*), 9/160 (4%) tigecycline R (*Kp, E. cloacae, A. baumannii*)               NA                                                                                                                                                                                                       13% at 21 days                                                             6/13 (46%) with CR-*Kp* vs. 3/20 (15%) with non CR-*Kp*; 14/19 (42%) with MDR *P. aeruginosa* vs. 2/16 (12%) with non-MDR *P. aeruginosa*   CR-GN BSI
                        (Pagano et al., 2014) ***Emerg Infect Dis***        01, 2009--12, 2012   Rome, Italy               NA                                                      *Kp*                                                                                                              81% colistin S, 69% tigecycline S, 65% gentamicin S                                                                              50% combined therapy with ≥2 active drugs                                                                                                                                                                21% (32/147)                                                               58% (15/26 KPC-*Kp*)                                                                                                                        NA
                        ([@B35]) ***Bone Marrow Transplantation***          01, 2010--07, 2013   Italy                     54 in auto-HSCT group; 43 in allo-HSCT group (median)   *Kp*                                                                                                              NA                                                                                                                               CR-*Kp*-targeted first line treatment in 6/25 (24%) auto-HSCT and 31/87 (36%) allo-HSCT patients, 11/112 tigecycline+ gentamicin, 3/112 colistin+ tigecycline+ gentamicin, 10/112 tigecycline+colistin   65/112                                                                     60/112                                                                                                                                      not CR-*Kp*-targeted first-line antibiotic therapy
                        ([@B80]) ***AJH***                                  01, 2010--06, 2014   Italy                     57% ≥55                                                 *Kp*                                                                                                              NA                                                                                                                               NA                                                                                                                                                                                                       101/278 (36%) at 21-days                                                   84/161 (52%) at 21 days                                                                                                                     CR BSI, septic shock, inadequate initial antimicrobial therapy
                        ([@B55]) ***BMC ID***                               02, 2012--05, 2013   Rome, Italy               54 \[28--76\] (mean, \[range\])                         *Kp*                                                                                                              12/22 colistin S, 6/22 tigecycline S and 0 gentamicin S                                                                          9/14 (64%) at least one drug active, 6 of which empirically                                                                                                                                              12/22                                                                      10/22 deaths due to CR-BSI                                                                                                                  AML
                        ([@B16]) ***Annals Hematology***                    03, 2015--08, 2015   Italy                     60 \[0--89\], (median \[range\])                        12 CR-BSI*:* 8 *Kp* 1 *Enterobacter sp.;* 2 *Acinetobacter Sp.;* 1 *P. aeruginosa*                                NA                                                                                                                               NA                                                                                                                                                                                                       10/144 (7%) at 30-days                                                     5/10 (50%) deaths due to CR BSI                                                                                                             NA
  **United States**     (Satlin et al., 2012) ***Leukemia and Lymphoma***   07, 2007--12, 2010   New-York, United States   56 \[24--77\] (median \[range\])                        14 *Kp*, 3 *E. cloacae*, 1 polymicrobial                                                                          80% colistin S, 65% tigecycline S, 30% gentamicin S                                                                              2/18 adequate empirical therapy 10/15 one active drug 5/15 two active drugs                                                                                                                              NA                                                                         10/18 (56%): 7 at 7 days, 9 at 14 days; 3 deaths before susceptibility data                                                                 NA

AL, acute leukemia; allo-, allogenic; AML, acute myeloid leukemia; auto-, autologous; BSI, blood steam infection; CR, carbapenem-resistant; GN, gram- negative; HSCT, hematologic stem cell transplantation; Kp, Klebsiella pneumoniae; MSR, multidrug resistant; R, resistant; S, sensitive.

###### 

Characteristics of the studies reporting CR bacteria in HM neutropenic patients.

  **Study**                               **Period**           **Place**                 **Type**                                  **Recruitment**                                              **Global effective**                                                                                                  **CR Effective**                                 **HM**                                                            **CR Species**                                                                                                                   **CR- Suscept ibility (S)**                                           **Thera -peutic regimens**                                                                                                                   **Mortality**                                  **CR- Mortality**                                           **Mortality risk factors**
  --------------------------------------- -------------------- ------------------------- ----------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  ([@B88]) ***Medicine***                 2008--2014           China                     retrospective monocentric                 BSI in febrile neutropenic HM patients undergoing HSCT       273 patients, 348 episodes of neutropenic fever, 85 neutropenic patients with BSI, 89 episodes of BSI, 108 isolates   12/108 (11%) isolates, 12/73 (16%) GN isolates   22 AML, 16 ALL, 13 lymphoma, 4 MM, 2 CML, 2 AA, 2 MDS, 4 others   4 *Kp* (16.7%), 3 *S. maltophilia*, 1 *P. aeruginosa, 1 C. freundii*, 1 *P. stutzeri*, 1 *A. baumannii* and 1 *C. indologenes*   NA                                                                    NA                                                                                                                                           11/85 (13%) patients with BSI cause of death   6/11 (55%) BSI-related deaths due to CR                     BSI with CR-bacteria and prolonged neutropenia (≥15 days, RR 16.7)
  ([@B27]) ***J Egypt Natl Canc Inst***   01, 2009--12, 2009   Cairo, Egypt              retrospective monocentric                 febrile neutropenia among HSCT recipients                    90 febrile neutropenia episodes in 50 patients, 39 BSI, 26 GN isolates                                                20% of GN bacteria                               24 AML, 12 ALL, 7 NHL, and 7 other HM                             NA                                                                                                                               NA                                                                    NA                                                                                                                                           5/50 (10%) with 60% infection attributed       NA                                                          NA
  ([@B46]) ***Eur J Haematol***           2002--2008           Stockholm Sweden          retrospective monocentric                 BSI in HM patients during chemotherapy-induced neutropenia   677 BSI episodes in 463 patients                                                                                      6 (1%) isolates                                  1/3 lymphoma, 1/3 AL, 1/3 MM or CLL                               1 *Enterobacter* spp. and 5 *P. aeruginosa*                                                                                      100% gentamicin S                                                     NA                                                                                                                                           5.2% at 7 days 13.6% at 30 days                NA                                                          NA
  ([@B78]) ***IJAA***                     2010- 2014           Athens, Greece            retrospective multicentric (4)            neutropenic HM patients with CR-*Kp* BSI                     NA                                                                                                                    50 patients                                      34 AML, 6 ALL, 1 CLL, 5 NHL, 1 MDS, 1 MM and 2 AA                 CR-Kp bacteremia                                                                                                                 90% gentamicin S, 86% tigecycline S, 74% colistin S                   33/50 (66%) empirical treatment with ≥one active drug, 40/50 (80%) definitive treatment with ≥one active drug, 30/50 combination therapy     50% at 14 days                                 50% at 14 days                                              unresolved neutropenia, septic shock, inadequate treatment, treatment with one active drug vs. combination
  ([@B69]) ***J infect***                 2008--2012           New York, United States   retrospective multicentric case control   neutropenic HM patients                                      1992 BSI                                                                                                              43 CR BSI (2%)                                   24 AML, 8 ALL, 8 lymphoma, 3 others 15 allo-HSCT, 3 auto-HSCT     30 *Kp*, 8 *E. cloacae*, 2 *E coli, 1 E. aerogenes, 1 E. gergoviae, 1 K. oxytoca* and 1 *S. marcescens*, 11 polymicrobial        tigecycline 86% S, polymyxin B 82% S, amikacin and gentamicin 48% S   6/43 (14%) active empirical treatment within 12h (vs. 56 to 88% in controls), median 52h \[IQR 33-69\] from BSI onset until active therapy   NA                                             22/43 (51%) at 30 days vs. 15% in controls (*p* \< 0.001)   CR-inactive empirical therapy

AA, aplastic anemia; AL, acute leukemia; ALL, acute lymphoid leukemia; allo-, allogenic; AML, acute myeloid leukemia; auto-, autologous; BSI, blood steam infection; CLL, chronic lymphocytic leukemia; CML, Chronic myeloid leukemia; CR, carbapenem-resistant; GN, Gram-negative;, HM, hematologic malignancy; HSCT, hematologic stem cell transplantation; Kp, Klebsiella pneumoniae; MDS, myelodysplatic syndrome; MM, myelome multiple; NHL, Non-Hodgkin's lymphoma, S, sensitive.

###### 

Characteristics of case reports studies reporting CR bacteria in HM patients.

                        **Study**                                                **Place**       **Year**     **Age (Y)**          **Hematologic malignancies**                               **Other conditions**                                  **Therapeutic antiobiotic administrated**                                                                                                                                                                                                     **CR Species**       **Sites of isolation**                                                     **Resistance mecanisms**               **Antimicrobial susceptibility**                                                                                                                                                 **Death**
  --------------------- -------------------------------------------------------- --------------- ------------ -------------------- ---------------------------------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -------------------------------------------------------------------------- -------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  **Asia**              ([@B4]) ***Infectious Diseases in Clinical Practice***   Japan           NA           55                   AML                                                        neutropenia 5 days after HSCT                         tigecycline                                                                                                                                                                                                                                   *Kp*                 stool, blood                                                               *bla*~*DHA--1*~ and Plasmid FIA(HI1)   tigecycline, colistin                                                                                                                                                            Yes
                        ([@B39]) ***Ann Clin Microbiol Antimicrob***             China           2014         30                   ALL                                                        previous exposure to colistin                         NA                                                                                                                                                                                                                                            *E. cloacae*         blood                                                                      IMI-1 variant                          ceftazidime, amikacin, ciprofloxacin, tigecycline, aztreonam, ceftriaxone, cefepime, piperacillin--tazobactam, gentamicin, tobramycin, levofloxacin, trimethoprim, minocycline   NA
                        ([@B95]) ***Emerging Microbes and Infections***          China           2014--2017   29                   AML monocytic                                              NA                                                    meropenem, isepamicin, vancomycin, teicoplanin, piperacillin-sulbactam, tigecycline, fosfomycin, amikacin, colistin, linezolid, polymyxin B                                                                                                   *Kp* (17 isolates)   fecal, blood, sputum                                                       KPC-2                                  tigecycline in strains 1 to 8, colistin in strain 1 to 9                                                                                                                         No
                        ([@B94]) ***IJID***                                      China           2014         56; 22; 63           AL                                                         imipenem and vancomycin prophylaxis                   NA                                                                                                                                                                                                                                            *E. coli*            blood                                                                      NDM-5                                  NA                                                                                                                                                                               NA
                        ([@B92]) ***Internal Medicine***                         China           2014--2016   40; 54; 59; 58; 44   T natural killer (NK) lymphoma, B lymphoma, ALL, AML, AA   1/5 agranulocytosis                                   Moxifloxacin--sulbactam/cefoperazone--tigecycline--fosfomycin--imipenem/cilastatin; meropenem--tigecycline; tigecycline--cefoperazone/sulbactam; moxifloxacin--amikacin; imipenem/cilastatin--vancomycin--tigecycline--amikacin--fosfomycin   *Kp*                 4 blood, 1 sputum                                                          KPC -2                                 100% tigecycline, 1/5 levofloxacin, 3/5 amiklin, 2/5 gentamicin, 2/5 vibramycin                                                                                                  4/5
  **Middel east**       ([@B43]) ***Molecular and Clinical Oncology***           Turkey          2015         50                   CML                                                        prior hospitalization in Libya                        tigecycline, meropenem, imipenem, gentamicin, sulbactam,                                                                                                                                                                                      *Kp*                 blood and valve                                                            NA                                     tigecycline                                                                                                                                                                      No
                        ([@B56]) ***IMAJ***                                      Israel          2012         64                   pro-B ALL                                                  neutropenia                                           piperacillin/tazobactam, vancomycin, meropenem, tigecycline, rifampicin and amikacin                                                                                                                                                          *Kp*                 blood, skin abscess                                                        NA                                     colistin, amikacin                                                                                                                                                               Yes
  **Northern europe**   ([@B52]) ***IJID***                                      Poland          2013         60                   AML                                                        neutropenia, trimethoprim and aciclovir prophylaxis   cefepime, amikacin, linezolid, teicoplanin, colistin, meropenem                                                                                                                                                                               *C. freundii*        urine                                                                      VIM-4                                  colistin                                                                                                                                                                         Yes
                        (Leitner et al., 2014) ***AAC***                         Austria         2011-2013    \[39-89\]            7 AML, 2 B-cell NHL, 1 myelodysplasia                      NA                                                    NA                                                                                                                                                                                                                                            *K. oxytoca*         blood, skin, stool, urine, abscess, bronchoalveolar lavage, throat, swab   KPC-2                                  amikacin, colistin fosfomycin                                                                                                                                                    4/11
  **Southern europe**   ([@B13]) ***Euro Surv***                                 Italy           2013         40                   ALL                                                        prior hospitalization in Belgrade                     piperacillin/tazobactam, amikacin, vancomycin, meropenem, colistin, tigecycline, rifampicin, daptomycin                                                                                                                                       *P. aeruginosa*      perianal abscess, blood                                                    NDM-1 ST235 strain                     colistin                                                                                                                                                                         Yes
                        ([@B62]) ***Microbial Drug Resistance***                 Spain           2015         36                   Myeloid sarcoma                                            ciprofloxacin prophylaxis                             piperacillin/tazobactam, amikacin, double- carbapenem regimen ertapenem + imipenem                                                                                                                                                            *Kp*                 urine                                                                      KPC-3                                  gentamicin, colistin, tigecycline                                                                                                                                                No
  **America**           ([@B70]) ***JCM***                                       United States   NA           70                   AML                                                        neutropenia                                           piperacillin/tazobactam, vancomycin, meropenem, trimethoprim- sulfamethoxazole, linezolid, amikacin                                                                                                                                           *E. gergoviae*       blood                                                                      KPC-3                                  levofloxacin, gentamicin, amikacin, tigecycline                                                                                                                                  Yes
                        ([@B18]) ***Rev Soc Bras Med Trop***                     Brazil          2010         94                   CLL                                                        NA                                                    ciprofloxacin, piperacillin/tazobactam, vancomycin                                                                                                                                                                                            *Kp*                 Urine                                                                      KPC-2                                  cefoxitin, cefepime, colistin, tigecycline                                                                                                                                       Yes

AA, aplastic anemia; AL, acute leukemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia; CML, Chronic myeloid leukemia; Kp, Klebsiella pneumoniae; NHL, Non-Hodgkin's lymphoma.

Epidemiology of Gram-Negative/Gram-Positive Infections Occurrence in HM Patients {#S3.SS1}
--------------------------------------------------------------------------------

There are epidemiologic specificities per regions of the world in the predominance of GN or Gram-positive (GP) causal pathogens responsible for (BSIs) in HM patients. Indeed, 62% of BSIs in HM patients in the United Kingdom were documented with GP strains ([@B71]), and such GP predominance was reported from Northern Europe and the United States ([@B46]; [@B71]; [@B69]). Conversely, GN isolates were responsible for more than 50% of BSIs in HM patients in Italy ([@B79]), Turkey ([@B44]), Egypt ([@B27]), and China ([@B88]). Therefore, the proportion of all CR pathogens is not comparable to the part of GN bacteria in areas with different epidemiology. These data highlight the need for clearer and more standardized measures, which is why we have been as exhaustive as possible in the reports of the studies' results in this review.

Carbapenem Resistance in Hematological Patients vs. the World *Geographical comparison* {#S3.SS2}
---------------------------------------------------------------------------------------

The emergence of resistance to carbapenems (imipenem, meropenem, ertapenem) is one of the most important problems with antibiotic resistance because there are few possible therapeutic alternatives. The resistance of GN bacteria to carbapenems may be due to several different mechanisms that confer a variable rate of resistance to this family of antibiotics, depending on how these mechanisms are expressed, that is, alone or in combination. This resistance can be due to structural mutations that affect the expression of some specific components of the membrane, such as efflux pump(s) and/or porins; a combination of these structural damages to the production of ESBLs or cephalosporinases; modification at the level of penicillin binding protein inducing a decrease in their sensitivity to the carbapenem molecules; and finally it can be due to the production of carbapenemase enzymes ([@B87]; [@B40]; [@B50]).

The production of carbapenemase enzymes is the most widespread mechanism of carbapenems resistance in the world, and their spread was mainly related to the GN bacteria, especially to Enterobacteriaceae. Based on the Ambler classification system, the carbapenemase belong to three different classes of β-lactamases: class A, class B, and class D β-lactamases.

Class A carbapenemase was either chromosomal encoded such as NmcA (non-metallo-carbapenemase-A), Sme (*Serratia marcescens* enzyme), IMI-1, and SFC (*Serratia fonticola* carbapenemase), or plasmid encoded such as GES (Guiana extended spectrum) and; KPC enzyme, which constitute the most transmissible and circulating class A carabapenemase enzyme in Enterobacteriaceae ([@B61]; [@B50]). Unlike classes A and D β-lactamase, which require serine at their active site, class B β-lactamase or MBL, require zinc to hydrolyze β-lactam ([@B50]). VIM, imipenem (IMP), and NDM enzymes are the MBL enzymes most often detected in GN bacteria ([@B61]; [@B50]). Finally, the class D carbapenemases, also known as oxacillinases, have been subdivided into different subgroups, some of which were of great clinical importance due to their wide acquisition by pathogenic bacteria. These important subgroups are mainly represented by oxacillinase (OXA)-23, OXA-24/40, OXA-48, OXA-51, OXA-58, and OXA-143 subgroups ([@B61]; [@B2]; [@B57]). This family has minimal activity on carbapenems compared to that of the KPC or NDM enzymes, except in the case where these enzymes are associated with other factors such as membrane impermeability ([@B57]).

We have represented in [Figure 1](#F1){ref-type="fig"}, the geographical distribution of the clinically important carbapenemase enzymes found in Enterobacteriaceae family, including OXA, KPC, IMP, NDM, and VIM enzymes. As it can be seen, in addition to sporadic cases, carbapenemase enzymes were found to be endemic or significantly spread in different continents of the world, such as North America (United States), South America (Colombia, Brazil, Argentina), Africa (Morocco, Egypt, Kenya, Senegal), Europe (Spain, France, United Kingdom, Germany, Poland, Norway, Sweden, Italy, and Spain), Asia (Turkey, Israel, India, China, Taiwan, Japan), and Australia ([Figure 1](#F1){ref-type="fig"}).

In order to identify the occurrence of CR in HM patients and to understand its epidemiology, we reviewed series and selected case reports that report colonization or infection of HM patients with CR bacteria. These studies were undertaken in different areas of the world, including New York, New Delhi, China, Stockholm, Frankfurt, Roma, Brescia, Athens, Ankara, Cairo, and Haifa in the series studies ([Tables 1](#T1){ref-type="table"}−3; [@B15], [@B16]; [@B46]; [@B71]; [@B68], [@B69]; [@B27]; [@B79], [@B80]; [@B88], [@B89]; [@B55]; [@B6]), and in United States, Brazil, Spain, Italy, Poland, Turkey, Israel, Japan, China, and Austria in the case reports ([Table 4](#T4){ref-type="table"}; [@B56]; [@B13]; [@B18]; [@B70]; [@B35]; [@B39]; [@B44]; [@B48]; [@B92]; [@B43]; [@B78]; [@B94], [@B95]; [@B52]; [@B62]; [@B4]). When we geolocate the regions that have reported the presence of CR bacteria in HM patients in [Figure 1](#F1){ref-type="fig"}, it can be observed that all these studies have been reported in regions that are either endemic or have a significant increase in carbapenemase enzymes (a coincidence with regions with high levels of CR bacteria) ([Figure 1](#F1){ref-type="fig"}).

For example, China and Italy are the two countries with the highest number of studies reporting cases of colonization or infection with CR bacteria in adult HM patients. The CR mechanism treated in these articles report the presence of the KPC (China and Italy), NDM (China and Italy), or IMI (China) enzyme type ([Figure 1](#F1){ref-type="fig"}).

From the viewpoint of the epidemiology of healthcare-associated infections, China and Italy are both endemic to at least two carbapenemase enzymes, namely KPC and VIM (Italy) or KPC and NDM (China). This supports our hypothesis that there is a relationship between the epidemiology of healthcare-associated infections and that one is found in MH patients.

It should be noted that in some areas of the world, where carbapenemase enzymes are either endemic (Argentina) or present a significant outbreak (Australia, Taiwan, Norway, France, Morocco, Senegal, Kenya, and Arabia Saudi) or both, as in Colombia, no data on the presence of CR bacteria in HM patients have been reported ([Figure 1](#F1){ref-type="fig"}). Therefore, the implementation of diagnostic and therapeutic tools, together with a monitoring system for CR in hematological units in these regions, is necessary.

The CR mechanisms of bacteria detected in HM patients are very rarely studied. Apart from the case reports that indicate this information, the series are more focused on the clinical aspect of the resistance in these patients (comorbidity, risk factors, mortality, and therapeutic strategies). The analysis of data extracted from case reports showed that the KPC enzyme was the predominant carbapenemase enzyme detected in CR bacteria isolated from HM patients ([Table 4](#T4){ref-type="table"}; [@B18]; [@B70]; [@B48]; [@B92]; [@B62]; [@B95]). When we compare this data with those related to the global distribution of carbapenemase worldwide, it is clear that the occurrence of the KPC enzyme in HM patients is related to its presence in the area (endemic or significant outbreak state) where the studies were conducted (China, Italy, Brazil, United States, Spain, Germany). Other carbapenemase enzymes have also been identified in CR bacteria isolated from HM patients, such as IMI ([@B39]), VIM ([@B52]), or NDM ([@B13]; [@B95]).

Overall, it appears that the resistance profile of strains involved in BSIs in patients with HM generally reflects the epidemiology of the country itself, with the exception of local outbreaks ([@B82]).

### Etiology of CR-Bacteria in HM Patients {#S3.SS2.SSS1}

In clinical settings, *K. pneumoniae* is considered an important opportunistic GN-pathogen, responsible for several nosocomial infections such as pneumonia, septicemia, and infections in newborns and intensive care patients ([@B63]). In HM patients, this species is the most widespread etiological bacterium in the world, detected in infections occurring in this group ([Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}). CR *K. pneumoniae* was detected mainly as rectal colonization ([@B16]; [@B42]), CR-bacteria BSIs ([@B69]), and nosocomial CR infection cases ([@B41]; [@B22]; [@B42]).

In Europe, several studies have reported the occurrence of CR bacteria, mainly represented by *K. pneumoniae* followed by *Klebsiella oxytoca*, *Citrobacter freundii*, and *P. aeruginosa* ([Tables 1](#T1){ref-type="table"}−4). Most of the investigations conducted on CR bacteria in HM patients were undertaken in Italy. Indeed, in this region, when we reviewed the long-term prospective or retrospective studies (2009--2019, 2010--2012, 2010--2014) ([@B83]; [@B79], [@B80]), we found that CR *K. pneumoniae* was the bacterial species most frequently responsible for infections (mainly BSIs) in HM patients identified at different rates \[12.4% ([@B83]), 35% ([@B79]), and 57.9% ([@B80])\]. In addition to CR *K. pneumoniae*, 70% of multidrug-resistant (MDR) *P. aeruginosa*, including those resistant to carbapenem involved in BSIs of HM patients, were reported in Italy ([@B15]; [@B79]).

In America, a few studies have reported the emergence of CR bacteria in HM patients. Most of them were undertaken in North America and more precisely in New York ([Figure 1](#F1){ref-type="fig"}; [Table 4](#T4){ref-type="table"}). The first study reported the occurrence of BSIs in neutropenic patients with acute myeloid leukemia (AML) due to the *Enterobacter gergoviae* strain producing the KPC-3 carbapenemase enzyme. This strain was nevertheless sensitive to levofloxacin, gentamicin, amikacin, and tigecycline ([Table 4](#T4){ref-type="table"}; [@B70]). *E. gergoviae* species is among the least common CR pathogens responsible for BSIs reported in neutropenic patients. The second study was a retrospective multicentric case control conducted over a 4-year period (2008--2012) on 1992 BSIs cases that occurred in neutropenic HM patients, where 43 cases (2.2%) of BSIs were reported to be due to CR bacteria, with the *K. pneumoniae* species predominating (68% of CR BSIs), followed by *Enterobacter cloacae* (18% of CR BSIs), *E. coli* (5% of CR BSIs), and others ([@B68]). The last study was a retrospective monocentric analysis that included 18 febrile neutropenic HM patients with CR BSIs, and as expected, the most frequently found etiological bacterium responsible for BSIs in these patients was *K. pneumoniae* (14 out of 18) followed by *E. cloacae* (3 out of 18) ([@B68]; [Table 4](#T4){ref-type="table"}). Only one study was conducted in Brazil (South America), in which the authors reported a KPC-producing *K. pneumoniae* collected during a urinary tract infection in a patient with chronic lymphocytic leukemia ([@B18]).

Unlike other continents, the etiology of CR related to HM patients in Asia is more diverse. When we examined the series and cases reports, different CR-bacterial species were detected in HM patients, including *K. pneumoniae* ([@B88]; [@B92]; [@B4]; [@B95]), *E. cloacae* ([@B39]), *E. coli* ([@B94]), and *A. baumannii* ([@B88]). These bacteria have been isolated either in a context of colonization (stool, sputum) or infection (mainly BSIs).

Neutropenia is the predominant condition in HM patients reported in the reviewed studies. CR BSIs in these patients have also been documented with less-frequent pathogens, such as *E. gergoviae*, *K. oxytoca*, *S. marcescens* ([@B69]), *Stenotrophomonas maltophilia*, *C. freundii*, *Pseudomonas stutzeri*, and *Chryseobacterium indologenes* ([@B88]).

Risk Factors for CR Bacterial Infection in HM Adult Patients {#S3.SS3}
------------------------------------------------------------

### Literature Review {#S3.SS3.SSS1}

In several areas, HM was reported as a significant risk factor for CR-Enterobacteriaceae positive culture, representing a comorbid condition in 8 to 27% of the hospitalized documented cases ([@B83]; [@B53]). In the 14-year prospective longitudinal surveillance study conducted in the United Kingdom, 2.5% of the GN pathogens isolated from bacteremia in HM patients were resistant to meropenem, compared to less than 1% in patients with solid cancer ([@B71]). In a prospective Italian cohort study conducted in nine hematology wards in 2009 to 2012, 21% of GN bacteria isolated from patients with BSIs (among 668 bacterial isolates) were resistant to meropenem. In a retrospective monocentric Turkish study on BSIs in HM patients over a 5-year period, 12% of GN-bacteria were resistant to meropenem ([@B44]).

Among all HM, the most at-risk population was on average 50 years old, mainly men, with acute leukemia (AL) or relapsed/refractory hematological disease ([Tables 1](#T1){ref-type="table"}−2). One study reported an age beyond 60 years as a major risk factor and lymphoma as protector ([@B16]). Factors significantly associated with CR infections were longer hospital stays before bacteremia, CR-bacteria carriage, previous CR isolate, urinary catheters, and AML ([Table 1](#T1){ref-type="table"}; [@B69]; [@B53]; [@B55]; [@B89]).

In hematological cohorts without specific recruitment, white blood count, central venous catheter, and previous antibacterial therapy, including recent carbapenem treatment or antibio-prophylaxis (mainly fluoroquinolones), were inconstant risk factors for the occurrence of invasive infection with CR bacteria ([@B1]; [@B55]; [@B16]), although these were frequent associated conditions ([Table 1](#T1){ref-type="table"}; [@B79]; [@B69]; [@B78]; [@B89]). This is in line with emerging data that tend to put antibiotic pressure in the background to explain the emergence of resistance ([@B23]). However, some regions of the world with the highest prevalence of CR bacteria (e.g., Asia, Middle East, North Africa, Central and South America) clearly do not overlap with regions of the world with the greatest access to and use of carbapenems in community-acquired infections ([@B64]; [@B86]). In a case-control study investigating risk factors for infection or colonization with CR *K. pneumoniae* conducted in Philadelphia, very few patients had a history of carbapenem use (1%) ([@B32]). Antibiotic resistance is probably not only selected by direct pressure during use but also results from complex interactions in natural populations and ecosystems ([@B38]). Moreover, a major bias of these studies is the restriction to healthcare-associated infections, and systematic exclusion of community acquired invasive infections, although community carriage is increasingly documented. This nosocomial recruitment obviously overestimates the role of prior exposition to antibiotics in the CR-bacteria sepsis occurrence.

A salvage chemotherapy was also associated with the occurrence of CR-bacterial infection ([@B1]). We hypothesize that the antibacterial properties of sequential chemotherapies could have an impact on the microbiomes of treated patients and alter the natural barriers that prevent endo-invasive infections with bacterial colonizers. Indeed, [@B31] highlighted in a prospective cohort of adults undergoing induction chemotherapy for AML, that a decrease in the Shannon diversity index of both oral and stool samples was a significant risk factor for subsequent infectious episodes, whereas neutropenia itself was not ([@B31]).

### Leukemias, Mainly Acute Myeloid Leukemia, at the Highest Risk {#S3.SS3.SSS2}

Similarly, as in series studied in our review, the majority of HM patients infected with CR bacteria in case reports had leukemias (19/26, 73%), mostly AML (12/19, 63%; [Table 4](#T4){ref-type="table"}). Specific alterations in the immunity of leukemia patients and the disease-induced neutropenia for prolonged periods may contribute to the increased risk of CR colonization and infection in this population. Leukemias account for 2.5% of all cancers and affect all aged groups ([@B12]). Leukemias are usually classified into four categories: acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), AML, and chronic myelogenous leukemia (CML). Among lymphocytic leukemias, CLL predominates and mostly concerns the elderly, 70 years being the median age at presentation; while 80% of ALL occur in less than 20 years old people. For unclear reasons, CLL is much rarer in Asian populations than in Western countries where it is the most common leukemia in adults ([@B65]; [@B66])^[3](#footnote3){ref-type="fn"}^.

Myelogenous leukemias are mainly adult diseases with a median age at presentation around 60. The most prevalent is AML, which involves the clonal expansion of myeloid blasts in the bone marrow and peripheral blood ([@B3]). Globally, AML represents 4 to 6% of HM and 30% of leukemias in adults, with a M/F ratio around 1.4 ([@B91]). Incidence of AML increases with age; while the relative survival dramatically reduces with age (50% at 6 months in older than 70 years) ([@B36]). Indeed, patients over 60 years of age more frequently present unfavorable chromosome abnormalities or co-morbid medical conditions that make it more difficult to use intense chemotherapy treatments ([@B25]). There are some worldwide disparities in AML distribution between countries with medium and low human development ([@B91]). The AML annual incidence is the highest in Europe \[2.5 to 5.5/100 000 age standardized rate (ASR)\] and the United States (3.7/100 000 ASR) compared to other areas (0.5 to 3.2/100 000 ASR) ([@B51]). Notably AML is less frequent in Morocco, Yemen, and China and affects younger people in Asia ([@B19]; [@B28]).

Unfortunately, no detailed world statistics are available for subclassified leukemias. We overlay the current endemic distribution of carbapenemases by country ([@B50]) with the global repartition of leukemia incidence ASR provided by the WHO and the International Agency for Research on Cancer 2019 (Data source GLOBOCAN 2018 available at <http://gco.iarc.fr/today>) in order to estimate the regions at most risk for CR-bacteria occurrence in hematologic patients ([Figure 2](#F2){ref-type="fig"}). This map brings out the United States, Italy, Greece, Turkey, Israel, and Taiwan as the countries with the highest risk for CR infections in HM patients.

![Global repartition of leukemia incidence age-standardized rate provided by the WHO, International Agency for Research on Cancer 2019 (Data source GLOBOCAN 2018 available at <http://gco.iarc.fr/today>), and the overlay of current endemic distribution of carbapenemases by country.](fmicb-11-01422-g002){#F2}

### Role of Carbapenem Resistance Colonization {#S3.SS3.SSS3}

Three studies demonstrated that CR carriage was a significant risk factor for CR BSI occurrence in HM patients ([@B1]; [@B80]; [@B42]). The rate of CR-bacteria colonization among HM patients at the admission ranged from 3.8% (85/2226)---in Italy, without association with previous exposure to antibiotics---to 21% (48/225) in India. In this Indian cohort, 20% (46/225) of patients acquired CR colonization during hospitalization ([@B42]). Of the colonized HM patients, 14% (12/85) developed a subsequent BSI with the same CR germ ([@B16]). Similarly, in a second study, 18% (17/94) of CR-colonized patients developed CR-bacteria BSIs, all of them during a course of therapy-induced neutropenia ([@B42]). Likewise, CR-*K. pneumoniae* colonization documented before or after transplant was followed by an infection in 26% of auto-hematopoietic stem cell transplantation (HSCT) and 39% of allo-HSCT CR-colonized patients ([@B35]). AL diagnosis, mostly AML, was the strongest risk factor for overall CR-bacteria colonization and bacteremia occurrence ([@B6]).

These data support the idea of implementing prevention strategies based on colonization surveillance and gut decontamination in CR-bacteria carriers with HM. It may be hypothesized that dysbiosis and damage of the mucosal surfaces combined with immunocompromised state associated with HM (mainly AL) and neutropenia increase the risk for CR-Enterobacterial invasive infection in colonized patients. Gut-decolonizing strategies against CR-Enterobacteria include antibiotics, bacteriophage therapy in trials, fecal microbiota transplantation, and alternative treatments such as probiotics or psyllium. Regimens with oral colistin sulphate and/or gentamicin and a regimen with streptomycin and neomycin have been used but with the risk of resistance development and with discordant results in terms of mortality reduction and clinical outcome according to the studies ([@B75]). Preventive strategies, such as fecal microbiota transplantation, have been reported to be safe and eradication of CR *K. pneumoniae* from the gastrointestinal tract was successful ([@B9]). However, the 2019 ESCMID-EUCIC clinical guidelines do not recommend the routine decolonization of MDR GN bacteria carriers, including immunocompromised carriers, regarding insufficient data for or against any intervention ([@B75]). Pending on reevaluation of these recommendations, CR-Enterobacteria positive patients should be put under barrier nursing care precautions as per Centers for Disease Control and Prevention guidelines (single room, dedicated nurse and housekeeping staff, contact isolation) ([@B17]). Control measures implementation, including weekly rectal screening and contact precautions, reduced significantly the spread of CR *K. pneumoniae* in patients with HM in an Italian teaching hospital ([@B55]).

### CR in Neutropenic Patients {#S3.SS3.SSS4}

Neutropenia is a major adverse effect of chemotherapy, HSCT, or disease course in HM patients, mainly AL ([Table 3](#T3){ref-type="table"}). Neutropenic cases belong to a subgroup of HM patients who are at particularly high risk of infection, including opportunistic and fungal pathogens. In the cohorts of neutropenic HM patients, CR BSI accounted for less than 1% of BSI in Northern Europe ([@B46]), 2% of BSI in New York ([@B69]), while 11% and 13% of BSI in China and Cairo, respectively ([Table 3](#T3){ref-type="table"}; [@B27]; [@B88]). In the multicentric retrospective American case control study, BSI due to CR bacteria over a 1-year period was of 1.8% in neutropenic HM patients vs. 0.7% in other types of hospitalized patients (*p* = 0.003), and factors independently associated with CR bacteremia in multivariable analyses were the use of a β-lactam/β-lactamase inhibitors or carbapenems within the previous 30 days and treatment with trimethoprim-sulfamethoxazole or glucocorticoids at BSIs onset ([@B69]). Likewise, in a meta-analysis of 30 studies, CR in neutropenic patients was associated with previous exposure to carbapenems (OR 4.63, 95% CI \[3.08--6.96\]), but this result relied on only four papers (13%) that had reported a significant association, none of them being prospective and half (2/4) failing to target HM patients ([@B64]).

As a result, neutropenic patients undergo multiple concurrent conditions, including antibiotics as prophylaxis or treatment, chemotherapy, and glucocorticoids that may contribute to promote CR-bacteria invasive disease while lacking immune defense mechanisms ([@B42]).

Management of CR-Infections in HM Adult Patients {#S3.SS4}
------------------------------------------------

Regarding antimicrobial susceptibility, CR strains in HM patients were globally susceptible to colistin (80--100%), tigecycline (60--80%), or gentamicin (10--60%) ([Tables 2](#T2){ref-type="table"}−4). The lowest rate of susceptibility to aminoglycosides was recorded in India ([@B42]) and Italy ([@B55]), where CR-*K. pneumoniae* isolates with high minimal inhibitory concentration to gentamicin, tigecycline, and colistin were reported ([@B22]). The worst resistance profile was observed by [@B55] with only half of CR-*K. pneumoniae* strains susceptible to colistin (12/22), 27% (6/22) to tigecycline, and none (0/22) to gentamicin ([@B55]).

In literature, focusing on CR-*K. pneumoniae*, a "targeted" antibiotic therapy, has been defined as an association of at least two antibiotics, including colistin, tigecycline, and gentamicin, with at least one of them active *in vitro* against the isolate ([@B85]; [@B35]). The standard therapy required in HM patients with documented CR-bacterial infection is the combination of: tigecycline--gentamicin / colistin--gentamicin / colistin--tigecycline--gentamicin / colistin--tigecycline / all ± in association with meropenem ([Table 2](#T2){ref-type="table"}). Indeed, the colistin--meropenem combination appeared synergistic *in vitro* against CR bacteria ([@B58]; [@B84]; [@B10]; [@B78]) but failed to be proven in trials ([@B59]), and *in vivo* synergisms have not been demonstrated ([@B24]). In a subgroup study, the use of colistin even against colistin-resistant isolates was a cornerstone in the treatment of CR *Acinetobacter* ([@B26]). The clinical efficacy of colistin in combination with rifampicin against colistin-resistant KPC-*K. pneumoniae* and VIM-1-producing *E. cloacae* has also been reported ([@B76], [@B77]). In ICU nosocomial CR-*K. pneumoniae* BSIs, high-dose regimens of tigecycline (200 mg loading dose followed by 100 mg/12 h) rather than standard dose (100 mg then 50 mg/12 h) were associated with significantly lower mortality without additional adverse effects ([@B34]).

Combination regimens are efficient in selected patients when antimicrobial susceptibility testing is available, but may have some toxicity, mainly renal. Empiric therapy first-line treatment in patients at-risk of infection with CR bacteria is challenging and could benefit from the arrival of new antibiotics active against CR-Enterobacteria and/or MDR *P. aeruginosa* and *A. baumannii*. However, recommendations and antimicrobial stewardship programs to position these therapeutic options are still lacking. Notably, additional data on clinical efficacy are needed for some of them ([@B60]). New β-lactamase inhibitors avibactam, relebactam, and vaborbactam can inhibit the activity of KPC-*K. pneumoniae*. Ceftazidime-avibactam was well tolerated and associated with higher clinical cure rates in HM patients with CR-enterobacteremia ([@B14]). However, its use can be associated with the emergence of resistance in patients with KPC-*K. pneumoniae*, so that it is recommended to associate ceftazidime-avibactam with other antibiotics such as tigecycline, aminoglycoside, colistin, or carbapenem. Moreover, ceftazidime-avibactam and meropenem-vaborbactam may lack activity against MBL (NDM and VIM) ([@B60]). Cefiderocol (S-649266), a novel siderophore cephalosporin, was stable against relevant carbapenemases, including MBL, KPC, and OXA-48-group carbapenemases. Ceftolozan-tazobactam could be a therapeutic option in non-carbapenemase-producing CR GN strains in HM patients ([@B67]); Non-β lactam antibiotics, plazomicin and eravacycline, also represent potential options for the treatment of CR GN-bacterial infections. Plazomicin is a new generation aminoglycoside with increased *in vitro* activity against KPC-producing bacteria, but with a limited activity against the NDM group of CR bacteria, and is currently recommended to treat urinary tract infections, but not BSI ([@B20]; [@B21]). Eravacycline is a novel fluorocycline structurally similar to tigecycline, not affected by most mechanisms causing tetracycline resistance, and has shown to be active against ESBL, KPC-, and OXA-producing Enterobacteriaceae ([@B93]).

In non-fermenter GN bacteria, colistin in combination with ceftazidime is clinically effective against MDR *P. aeruginosa* ([@B76], [@B77]). New antimicrobial molecules can inhibit the activity of some non-fermenter GN bacteria. [@B37] showed the success of ceftolozane, a novel cephalosporin, used in combination with tazobactam for the treatment of MDR *P. aeruginosa* infections in hematopoietic-cell transplant recipients ([@B37]). Unlike in *P. aeruginosa*, eravacycline (the novel fluorocycline) is active against MDR *A. baumannii* and *S. maltophilia* ([@B93]).

It should be noted that active empiric therapy was rarely administrated in HM patients with CR BSIs: 34% in an Israeli study ([@B1]), 24% in an Italian HCST cohort ([@B35]), and only 14% vs. 56 to 88% in hematological controls with non-CR BSIs (*p* \< 0.001) in neutropenic American patients ([@B69]; [Tables 2](#T2){ref-type="table"}−3). For high-risk neutropenic patients, all of the guidelines recommend starting monotherapy with a beta-lactam active against *P. aeruginosa* (piperacillin-tazobactam, imipenem, meropenem, cefepime, ceftazidime) and to add other antimicrobials in patients who are clinically unstable and when there is suspicion of infection caused by resistant GN or GP bacteria ([@B30]; [@B33]). But even after susceptibility data, few HM patients received optimal antibiotic therapy. In the cohort of 50 neutropenic HM patients with CR-*K. pneumoniae* BSIs, 90, 86, and 74% of the isolates were susceptible to gentamicin, tigecycline, and colistin, respectively. However, for definitive treatment, 80% received at least one active drug, and only 60% of patients received a combination therapy ([@B78]). In the New York series, 80% of CR Enterobacteria were susceptible to colistin, 65% to tigecycline, and 30% to gentamicin, but only 5/15 (33%) received two targeted agents ([@B68]).

Therefore, providing adequate treatment for patients with CR bacteria, not only at the time of empirical antibiotic therapy but also after susceptibility test results, remains a real therapeutic challenge. HM patients with CR infection would really benefit from the early help of infectious diseases consultants ([@B22]) and should be approached according to the algorithm proposed in [Figure 3](#F3){ref-type="fig"}.

![Proposal for CR-bacterial infection risk assessment and empirical management of febrile hematologic patients, based on morbidity and mortality determinants recorded from this literature review.](fmicb-11-01422-g003){#F3}

Factors of Mortality in HM Patients With CR Bacterial Infections {#S3.SS5}
----------------------------------------------------------------

We found the overall mortality rate of HM patients ranged from 7 to 55% according to the series, and mortality was much higher (45 to 100%) among CR-infected HM patients ([Tables 2](#T2){ref-type="table"}−3). Among CR bacteria, mortality was linked with CR *K. pneumoniae* and CR *A. baumannii*, which were identified as independent risk factors for 30-day mortality in HM patients ([@B89]). The CR-related mortality rate was particularly high in allo-HSCT patients (64.4% at 3 months) and in neutropenic patients: for example, 51% at 30 days vs. 15% in controls (*p* \< 0.001) and 50 vs. 13% in overall BSI-related mortalities ([Table 3](#T3){ref-type="table"}; [@B68]; [@B88]; [@B80]; [@B45]). In comparison, in a review of studies published worldwide before 2012, [@B29] estimated that 26 to 44% of deaths worldwide were due to CR ([@B29]), and [@B11] reported the highest attributable mortality rate for CR-*K. pneumoniae* bacteremia in all comorbidities as 50% with a mortality risk ratio of 3.3 (95% CI, 2.9--28.5) ([@B11]). Moreover, in a carbapenemase non-endemic European country, CR-colonized HM patients had a significantly reduced 60- and 90-day, as well as 1- and 2-year survival rates when compared to non-colonized patients ([@B6]).

It is worth noting that the methods and timing of outcome measurement differ from one study to another and that the age range of the population is often extended across cohorts ([Tables 2](#T2){ref-type="table"}−3). However, in assessing mortality factors in patients with HM, it is important to take into account the classification and progression of the disease by WHO and the age of the patients, especially in the case of AML where age and neutropenia have a significant impact on survival rates as explained above ([@B25]).

Three studies reported CR-inactive empirical therapy as an independent risk factor of mortality ([@B29]; [@B35]; [@B80]). One study demonstrated inadequate treatment and the absence of active drug combination as a significant risk of death with a mortality rate up to 90% in neutropenic patients with inadequate treatment ([@B78]). Likewise, studies investigating intensive care unit patients have demonstrated that the use of combinations with CR *K. pneumoniae*-targeted antibiotics are associated with increased survival of patients with BSIs ([@B85]). In the Indian prospective series reporting a global infection-related mortality at 26 months as 9.5% (22/225) with 77% of deaths (17/22) due to CR-bacteria BSIs, the mortality in HM patients with CR bacteremia was 100% in a median time of 6 days, with 100% of strains susceptible to colistin and 65% to tigecycline, but the antibiotic therapies and delay of introduction were not specified ([@B42]). In the Italian multicentric study, the overall 21-day mortality rate in HM patients with bacterial BSIs was significantly higher for patients with BSIs caused by CR Enterobacteriaceae vs. non-CR strains, but no treatment was detailed ([@B79]). Besides, ([@B68]) reported a 40% mortality rate at 7 days in CR BSI and explained that only 2/18 (11%) of patients had received an adequate empirical therapy. Three deaths occurred before susceptibility data, the median time to introduce an active drug after susceptibility results was 55 h, and only one-third of survivors finally received two active agents representing less than 30% of CR-infected HM patients in this study ([@B68]).

Moreover, in the specific population of neutropenic patients, unresolved neutropenia (i.e., \>14 days) was an independent predictor of death ([@B88]; [@B78]). In Jaiswal's cohort, all CR bacteremia occurred in CR-bacteria carriers during neutropenia, which appears to be a promoting factor of CR-infection occurrence and severity ([@B42]). Others factor of death were nosocomial acquisition of CR bacteria ([@B42]) and AML ([@B55]).

Therefore, the delay and the combination of active antimicrobial therapy in HM patients with CR GN bacterial infections, especially if associated with conditions at higher risk of mortality (profound neutropenia, HSCT, AML, and elderly people) exposes them to increased morbidity and mortality. Treatment failures do not appear to be due to a "therapeutic impasse," but most deaths have occurred in vulnerable HM patients without adequate antibiotic treatments being introduced in time.

Conclusion and Strategies {#S4}
=========================

As proved with broad-spectrum beta-lactam-resistant Enterobacteria ([@B90]), close monitoring CR intestinal carriage can help control their spread and decide on the appropriate initial antimicrobial treatment for vulnerable HM patients with infection. Surveillance of gut colonization in HM populations, at the time of diagnosis and along the course of chemotherapeutic lines and hospitalizations, should be implemented in the most at risk areas we identified (high incidence of carbapenemase bacteria and leukemias), but also in those with a low prevalence of CR to monitor the risk of CR BSI occurrence in HM patients per regions ([@B6]).

Importantly, the most at-risk patients should be early identified since the first-line CR-bacteria-targeted treatments do not correspond to standard empiric antibiotic therapies recommended in HM patients, and CR-bacteria identification takes at least 48 h, while time is counted in this group ([@B73]; [@B5]). A critical aspect for the management of CR pathogens in HM patients and the reduction of the related mortality is the definition of early therapeutic strategies based on timely empiric antibiotic combinations, including tigecycline and colistin +/-- aminoglycosides, or new drugs such as ceftolozan-tazobactam and ceftazidime-avibactam, according to the antimicrobial susceptibility profiles locally documented. Based on the determinants recorded from this literature review, we propose an algorithm assessing the incremental risk for CR-bacterial infection occurrence and mortality in febrile hematologic patients, guiding the empirical therapeutic strategies ([Figure 3](#F3){ref-type="fig"}).

Finally, the mechanisms (whether it is carbapenemase production or not) and the genetic support of the resistance to carbapenems were poorly documented in the clinical series of HM patients ([@B68]; [@B35]; [@B78]). However, the way GN bacteria resist carbapenems may play a role in the antibiotic combination synergies. Clinical trials and studies on therapeutic efficacy should integrate epidemiological data regarding the existing diversity of resistance mechanisms and profiles in CR Enterobacteriaceae ([@B72]).
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